Computational drug repositioning for cancer therapeutics

Due to ever-increasing failure rates, high cost, unsatisfactory safety profile, and limited efficacy associated with anticancer drug development, the repositioning of established non-cancer drugs for new oncology indications has emerged as an increasingly attractive approach to addressing the unmet...

Full description

Saved in:
Bibliographic Details
Published inCurrent topics in medicinal chemistry Vol. 15; no. 8; p. 767
Main Authors Jiao, Mingkun, Liu, Gang, Xue, Yu, Ding, Chunyong
Format Journal Article
LanguageEnglish
Published United Arab Emirates 01.01.2015
Subjects
Antineoplastic Agents - chemistry
Antineoplastic Agents - pharmacology
Computational Biology
Drug Discovery - methods
Drug Repositioning
Humans
Molecular Targeted Therapy
Online AccessGet more information

Cover

More Information
Summary:Due to ever-increasing failure rates, high cost, unsatisfactory safety profile, and limited efficacy associated with anticancer drug development, the repositioning of established non-cancer drugs for new oncology indications has emerged as an increasingly attractive approach to addressing the unmet cancer-related medical need. With the rapid development of bioinformatics, chemoinformatics as well as high-performance computing, drug repositioning is becoming more intentional than ever, and a significant surge of computational approaches has been well established to greatly facilitate drug repositioning for cancer treatment. In this review, we provide a brief overview of recent advances in the computational drug repositioning for anticancer applications with a specific emphasis on repositioning of non-cancer drugs by use of various computational approaches.
ISSN:1873-4294
DOI:10.2174/1568026615666150302105831